The Company That Was Supposed to Win
In 2013, the race to commercialize CRISPR gene editing was just beginning. Feng Zhang at the Broad Institute had published a landmark paper demonstrating that CRISPR-Cas9 could edit human cells, and the patent filings were already in motion. That same year, Editas Medicine was founded with an extraordinary roster of scientific talent and what appeared to be an insurmountable intellectual property advantage. The company's founding scientific advisors included five pioneers of CRISPR technology: Feng Zhang, George Church, J. Keith Joung, David Liu, and Jennifer Doudna — though Doudna would leave before the company's public debut amid the intensifying patent dispute between the Broad Institute and UC Berkeley.
By any reasonable measure, Editas should have been the company to define the CRISPR therapeutics industry. It had first-mover advantage, elite science, and a privileged relationship with the Broad Institute's patent portfolio. Instead, as of early 2026, Editas finds itself without an approved product, with a stock price that has fallen from peaks above $70 to single digits, and with competitors who started later having already crossed the finish line with FDA-approved therapies.
What went wrong? The answer involves a combination of scientific ambition, strategic miscalculation, leadership instability, and the brutal economics of drug development.
The Founding and Early Promise (2013-2016)
Editas Medicine was incorporated in November 2013 with $43 million in Series A funding from Flagship Pioneering, Polaris Partners, and Third Rock Ventures — three of the most respected life sciences venture firms in the world. The company's founding thesis was straightforward: license the Broad Institute's CRISPR-Cas9 intellectual property and build a pipeline of gene editing therapies across multiple disease areas.
The early team was remarkable. Beyond its scientific advisory board, Editas recruited Katrine Bosley as CEO, a veteran biotech executive who had led Avila Therapeutics. The company set up operations in Cambridge, Massachusetts, steps from the Broad Institute, and began building out its platform.
In February 2016, Editas became the first CRISPR-focused company to go public, raising $94 million in its IPO on the Nasdaq. The stock surged on its first day of trading, reflecting intense investor enthusiasm for gene editing technology. At its peak in 2016, shares traded above $40 — and would climb higher in subsequent years as CRISPR mania gripped the biotech market.
The timing was significant. CRISPR Therapeutics, co-founded by Emmanuelle Charpentier, had been incorporated in 2013 as well, but didn't IPO until October 2016. Intellia Therapeutics, co-founded by Jennifer Doudna, went public in May 2016, just months after Editas. By going first, Editas established itself as the standard-bearer for the CRISPR therapeutics industry.
But being first to the stock market is not the same as being first to the clinic, and the strategic choices Editas made in its early years would have lasting consequences.
EDIT-101 and the BRILLIANCE Trial: Reaching for the Hardest Problem
Editas made a bold bet with its lead program: EDIT-101, a therapy for Leber congenital amaurosis type 10 (LCA10), a rare inherited form of childhood blindness caused by mutations in the CEP290 gene. The program was historically significant — it would become the first attempt to use CRISPR gene editing inside a living human body (in vivo), delivered directly to the retina via subretinal injection using an adeno-associated virus (AAV) vector.
The ambition was audacious. While CRISPR Therapeutics was pursuing an ex vivo approach for sickle cell disease — extracting patient cells, editing them in the lab, and reinfusing them — Editas chose a fundamentally harder path. In vivo editing requires delivering the CRISPR machinery to the correct cells inside the body, achieving efficient editing in the target tissue, and doing so without causing damage to surrounding cells. In 2017, when Editas selected this program as its lead, no one had ever done this in humans.
The BRILLIANCE trial, which dosed its first patient in March 2020, was a watershed moment for the entire gene editing field. The concept of editing DNA inside a living person's body captured both scientific and public imagination.
But the clinical results, when they came, were humbling.
Data presented at medical conferences in 2022 and 2023 showed that EDIT-101 was generally well-tolerated from a safety perspective. However, the efficacy was modest at best. Some patients showed improvements in light sensitivity, but the functional visual gains were limited and inconsistent. The editing efficiency achieved in the retinal cells was lower than hoped, and the clinical benefit did not reach the threshold that would support regulatory approval without significant further development.
In 2023, Editas announced it would not advance EDIT-101 further as a standalone program. The company pivoted to next-generation in vivo approaches, effectively shelving the program that had defined its identity for years.
The BRILLIANCE trial was not a failure in the traditional sense — it provided valuable proof-of-concept data for in vivo CRISPR editing and generated important safety information. But in the competitive calculus of the biotech industry, it was a devastating setback. While Editas spent years and hundreds of millions of dollars on a program that yielded modest results, CRISPR Therapeutics and Vertex Pharmaceuticals were marching toward FDA approval for Casgevy.
EDIT-301 and Reni-cel: Playing Catch-Up in Sickle Cell Disease
Recognizing the limitations of its in vivo-first strategy, Editas also developed an ex vivo program: EDIT-301, later branded as reni-cel (renizgamglogene autotemcel), for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia.
Reni-cel used a differentiated approach from Casgevy. While Casgevy employs the standard SpCas9 enzyme (derived from Streptococcus pyogenes), reni-cel used Cas12a (also known as Cpf1), a different CRISPR nuclease discovered in Feng Zhang's laboratory. The Cas12a enzyme offered potential advantages: it naturally processes its own guide RNA arrays, enabling multiplex editing, and it creates staggered cuts in DNA rather than the blunt-end cuts made by Cas9.
Like Casgevy, reni-cel targeted the BCL11A gene to reactivate fetal hemoglobin production in patients' hematopoietic stem cells. Early clinical data from the EdiTHAL and RUBY trials showed that reni-cel could indeed boost fetal hemoglobin levels and reduce disease symptoms. Some patients achieved transfusion independence or freedom from vaso-occlusive crises.
But there was a fundamental problem: reni-cel was years behind Casgevy.
In December 2023, the FDA approved Casgevy for sickle cell disease and transfusion-dependent beta-thalassemia. Editas was still enrolling patients in its clinical trials. Even if reni-cel showed equivalent or superior results, it would be entering a market where an approved product already existed. For a therapy that requires myeloablative conditioning (intensive chemotherapy to destroy the patient's bone marrow before infusion of edited cells), the bar for a second entrant is extraordinarily high. Physicians and patients generally default to the approved, known quantity unless a challenger demonstrates a clear and compelling advantage.
By mid-2024, the competitive dynamics were stark. Casgevy was commercially available. Bluebird Bio's Lyfgenia offered an alternative gene therapy for SCD. And Beam Therapeutics was advancing its own base editing approach (BEAM-101) for the same indication. Reni-cel, despite its scientific merits, was one of several late entrants into an increasingly crowded field.
Leadership Instability: The CEO Carousel
One of the most visible symptoms of Editas's struggles was persistent leadership turnover. In biotech, CEO transitions are not uncommon, but the frequency and circumstances at Editas were unusual.
Katrine Bosley (2014-2019) led the company through its founding, IPO, and the initiation of the BRILLIANCE trial. She departed in 2019, replaced by Cynthia Collins.
Cynthia Collins (2019-2021) came from Bayer's cell and gene therapy division and oversaw the early clinical development of both EDIT-101 and EDIT-301. She left in 2021 after approximately two years.
Gilmore O'Neill (2021-2023) was promoted from within, having served as chief medical officer. He led the company through the disappointing BRILLIANCE readouts and the strategic pivot away from EDIT-101 as a lead program. He departed in 2023.
Tony Ho (2023-present) took the helm amid the company's most challenging period, tasked with restructuring the pipeline and stabilizing the business.
Four CEOs in a decade signals deeper organizational challenges. Each transition consumed management bandwidth, disrupted strategic continuity, and eroded investor confidence. In the biotech industry, where clinical development programs span many years and require consistent strategic vision, leadership churn is particularly damaging. It becomes difficult to execute a coherent long-term strategy when the person setting that strategy changes every two to three years.
The leadership instability also reflected the board's evolving assessment of what Editas needed at each stage — and perhaps an underlying uncertainty about the company's strategic direction.
The Patent Question: Strength or Liability?
Editas Medicine was founded, in large part, on the strength of the Broad Institute's CRISPR-Cas9 patent portfolio. Feng Zhang's group at the Broad filed patent applications and received key U.S. patents covering the use of CRISPR-Cas9 in eukaryotic cells, including human cells. Editas held an exclusive license to these patents for therapeutic applications.
For years, this patent position was presented as Editas's crown jewel. In the bruising patent interference proceedings between the Broad Institute (Zhang) and UC Berkeley (Doudna and Charpentier), the Broad repeatedly prevailed before the U.S. Patent Trial and Appeal Board (PTAB). The PTAB ruled in 2017 that there was no interference between the two sets of patents — a decision upheld on appeal — and in a subsequent proceeding in 2022, the PTAB ruled in the Broad's favor again on priority for certain claims.
But the patent advantage proved more complicated than it initially appeared.
First, the patent landscape was fragmented. While the Broad held important U.S. patents, the European Patent Office (EPO) revoked some of the Broad's key European patents, and UC Berkeley held significant patent rights in Europe and other jurisdictions. This meant that Editas's patent advantage was largely a U.S.-centric asset, limiting its value in the global pharmaceutical market.
Second, the practical value of CRISPR patents for blocking competitors turned out to be limited. CRISPR Therapeutics and Intellia Therapeutics, both aligned with the UC Berkeley/Doudna patent estate, were able to develop and commercialize CRISPR therapies without being stopped by the Broad's patents. Cross-licensing, freedom-to-operate opinions, and the sheer complexity of the patent landscape meant that no single patent holder could effectively exclude competitors from the field.
Third, Editas's dependence on licensed — rather than owned — intellectual property created structural complexity. The Broad Institute retained ownership of the patents, and the terms of Editas's license included milestone payments, royalties, and conditions that added cost and reduced flexibility.
In hindsight, the CRISPR patent portfolio was never the competitive moat that investors hoped it would be. In biotechnology, patents protect specific compositions and methods, but they cannot substitute for clinical execution, commercial capability, and pipeline strategy.
Financial Deterioration and the Stock Price Collapse
The financial trajectory of Editas Medicine tells a stark story. The company's stock reached its all-time high above $70 per share in early 2021, during the broader biotech and CRISPR enthusiasm that accompanied the COVID-19 mRNA vaccine success (which validated genetic medicine broadly) and the excitement around the BRILLIANCE trial.
From that peak, the decline was relentless:
- 2021-2022: The stock fell as early BRILLIANCE data disappointed and the broader biotech sector corrected from its COVID-era highs
- 2022-2023: Further declines as Editas announced the deprioritization of EDIT-101 and investors recognized that reni-cel would be a late entrant to the SCD market
- 2023-2024: The approval of Casgevy crystallized the competitive disadvantage, and restructuring announcements further pressured the stock
- 2024-2025: Shares traded in single digits, reflecting deep skepticism about the company's path to value creation
By late 2025, Editas had a market capitalization below $300 million — a fraction of CRISPR Therapeutics (over $3 billion) or Intellia Therapeutics (over $2 billion). For a company that had once been valued comparably to these peers, the divergence was staggering.
The financial challenges extended beyond the stock price. As a pre-revenue biotech company, Editas relied on equity offerings and partnerships to fund operations. A declining stock price makes equity financing increasingly dilutive to existing shareholders, creating a vicious cycle: poor clinical results lead to stock declines, which make fundraising more expensive, which constrains the ability to fund the clinical programs needed to reverse the stock decline.
Editas undertook multiple rounds of layoffs and restructuring to extend its cash runway, reducing headcount and narrowing its pipeline focus. These are necessary survival measures, but they also signal to the market that the company is in contraction mode rather than growth mode.
What Went Wrong: A Systematic Analysis
The Editas story is not one of a single catastrophic failure. It is the accumulation of strategic choices that, in aggregate, left the company behind its competitors.
1. Choosing the hardest problem first
Editas's decision to lead with in vivo retinal editing (EDIT-101) was scientifically admirable but commercially questionable. LCA10 is an ultra-rare disease with a tiny patient population. In vivo editing in 2017 was untested in humans. The AAV delivery to the retina, while more targeted than systemic delivery, still presented enormous technical challenges. By contrast, CRISPR Therapeutics chose ex vivo editing for sickle cell disease — a technically more established approach with a larger patient population and a clearer regulatory pathway.
2. Underestimating the speed of competitors
Editas appeared to operate under the assumption that its patent position and first-mover status provided a durable competitive buffer. They did not. CRISPR Therapeutics moved aggressively through clinical development, partnered with Vertex Pharmaceuticals (a large pharma company with regulatory and commercial expertise), and reached FDA approval years ahead of Editas's ex vivo program.
3. In vivo delivery remains unsolved
The fundamental challenge of in vivo CRISPR editing — delivering the editing machinery to the right cells inside the body with sufficient efficiency and specificity — remains one of the hardest problems in biotechnology. Editas bet heavily on this approach before the delivery technology was mature. Intellia Therapeutics, which also pursues in vivo editing, benefited from using lipid nanoparticle (LNP) delivery to the liver, a comparatively more tractable target organ. Editas's retinal approach, while elegant, proved insufficient for robust clinical benefit.
4. Patent assets did not translate to competitive advantage
As discussed above, the Broad Institute patents did not block competitors or generate meaningful licensing revenue. The IP position was a necessary condition for operating in the CRISPR space but not a sufficient one for building a leading company.
5. Leadership continuity was lacking
Four CEOs in a decade made it difficult to maintain strategic discipline. Each new leader brought a different perspective and often initiated strategic shifts, consuming time and resources that could have been directed toward clinical execution.
How Competitors Pulled Ahead
The contrast with Editas's peers is instructive.
CRISPR Therapeutics partnered with Vertex Pharmaceuticals early, gaining access to a large pharma partner's clinical development, regulatory, and commercial capabilities. The company chose sickle cell disease — a well-understood indication with a large, motivated patient population and clear clinical endpoints. Casgevy received FDA approval in December 2023, making CRISPR Therapeutics the first company to bring a CRISPR therapy to market.
Intellia Therapeutics focused on in vivo editing but chose the liver as its target organ and transthyretin amyloidosis (ATTR) as its lead indication. The liver is the most accessible organ for LNP-mediated delivery, and ATTR has a clear biomarker (TTR protein levels) that enables rapid proof-of-concept. By 2025, Intellia had compelling pivotal trial data for its lead program, NTLA-2001, and was advancing toward a potential regulatory filing.
Both competitors made strategically sound choices: accessible target organs, well-characterized diseases, clear clinical endpoints, and strong partnerships. Editas, by contrast, chose ambition over accessibility at nearly every turn.
Lessons for Biotech Investors
The Editas story offers several durable lessons for investors in the gene editing and broader biotech sectors.
First-mover advantage is overrated in therapeutics. Unlike technology companies, where being first to market can create network effects and switching costs, first-mover advantage in drug development is limited. What matters is being the first to achieve regulatory approval with a differentiated product. Editas was first to IPO and first to dose a patient with in vivo CRISPR, but these milestones did not translate to commercial value.
Patents are not products. Intellectual property is necessary but not sufficient. The value of a biotech company ultimately depends on its clinical data, not its patent portfolio. Investors who weighted Editas's Broad Institute license too heavily in their valuation models were overexposed to a non-productive asset.
Indication selection is a strategic act. The choice of which disease to target first is arguably the most important decision a biotech company makes. It determines the regulatory pathway, the competitive landscape, the patient population, the clinical endpoints, and the commercial opportunity. Editas's choice of LCA10 as its lead indication was brave but suboptimal from a risk-return perspective.
Leadership stability correlates with execution. Clinical drug development requires years of sustained, disciplined execution. Companies with stable leadership teams tend to navigate the inevitable setbacks of drug development more effectively than those in constant transition.
Cash runway matters more than market cap. In a declining stock environment, the ability to fund operations without catastrophic dilution becomes the central question. Investors should always track a biotech company's cash position and burn rate alongside its clinical milestones.
Current Status and Future Prospects
As of early 2026, Editas Medicine is a company in transformation. Under CEO Tony Ho, the company has narrowed its pipeline and is exploring strategic alternatives to maximize the value of its remaining assets.
The reni-cel program continues in clinical development for sickle cell disease, though its commercial prospects are constrained by the head start enjoyed by Casgevy and the advancing programs from Beam Therapeutics and others. Editas's next-generation in vivo editing programs, leveraging newer CRISPR systems and improved delivery technologies, represent longer-term opportunities but are in earlier stages of development.
The company's Broad Institute patent license remains a potentially valuable asset, particularly if the CRISPR patent landscape consolidates or if cross-licensing agreements generate meaningful revenue. However, this is speculative and depends on factors largely outside Editas's control.
There are scenarios in which Editas could recover value. A strong clinical readout for reni-cel, a transformative partnership or acquisition, or a breakthrough in delivery technology could change the narrative. The underlying science is sound, and the company retains talented scientists and engineers. But the window for an independent Editas to compete with its better-capitalized, more advanced peers is narrowing.
Some industry observers have speculated that Editas could ultimately be acquired by a larger pharmaceutical or biotechnology company seeking access to its IP portfolio, its Cas12a platform, or its clinical programs. In the gene editing sector, where foundational technology platforms are scarce, even a struggling company can have significant acquisition value.
The Broader Significance
The Editas story is, in some respects, a microcosm of the entire gene editing industry's maturation. The early years of CRISPR commercialization were characterized by extraordinary hype, massive capital inflows, and the assumption that transformative science would naturally lead to transformative companies. Reality proved more complicated.
Translating a laboratory breakthrough into an approved, commercially viable medicine requires not just scientific excellence, but also strategic discipline, clinical execution, regulatory expertise, and commercial infrastructure. The companies that have succeeded — CRISPR Therapeutics with Casgevy, Intellia with its advancing ATTR program — are those that made pragmatic choices about indication selection, partnered effectively, and maintained strategic focus over many years.
Editas Medicine may yet find its footing. The CRISPR editing field is still young, and the addressable disease areas are vast. But the company's journey from the "first CRISPR company" to a cautionary tale in biotech strategy offers lessons that extend far beyond a single stock ticker.
Disclaimer: This article is for informational and educational purposes only and does not constitute financial or investment advice. The gene editing sector carries significant risks, including clinical, regulatory, and commercial uncertainty. Always consult a qualified financial advisor before making investment decisions.
Sources
-
Editas Medicine S-1 Filing, SEC.gov (2016). https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&company=editas+medicine
-
Maeder, M.L., et al. "Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10." Nature Medicine 25, 229-233 (2019). https://doi.org/10.1038/s41591-019-0377-7
-
Pierce, E.A., et al. "Gene Editing for CEP290-Associated Retinal Degeneration." The New England Journal of Medicine (2023). https://doi.org/10.1056/NEJMoa2309915
-
Frangoul, H., et al. "CRISPR-Cas9 Gene Editing for Sickle Cell Disease and Beta-Thalassemia." The New England Journal of Medicine 384, 252-260 (2021). https://doi.org/10.1056/NEJMoa2031054
-
U.S. Patent and Trademark Office. "Patent Interference No. 106,115 — The Broad Institute v. UC Berkeley." PTAB Decision (2017; affirmed 2018). https://www.uspto.gov/patents/ptab
-
FDA Press Release. "FDA Approves First Gene Therapies to Treat Sickle Cell Disease." (December 8, 2023). https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapies-treat-sickle-cell-disease
-
Editas Medicine Annual Report 10-K, SEC.gov (2024). https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&company=editas+medicine
-
Sheridan, C. "The world's first CRISPR therapy is approved: who will receive it?" Nature Biotechnology 42, 3-4 (2024). https://doi.org/10.1038/d41587-023-00016-6
-
Gillmore, J.D., et al. "CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis." The New England Journal of Medicine 385, 493-502 (2021). https://doi.org/10.1056/NEJMoa2107454
-
Cohen, J. "The CRISPR patent battle is over. Here's what it means." Science (2022). https://www.science.org/content/article/crispr-patent-battle-over
-
Zetsche, B., et al. "Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System." Cell 163, 759-771 (2015). https://doi.org/10.1016/j.cell.2015.09.038
-
Evaluate Pharma. "Gene Editing Market Landscape and Competitive Analysis." (2025). https://www.evaluate.com
